Changing Paradigms in the Managementof Diabetic Macular Edema
Dr. Manoj Khatri
Diabetes mellitus is a chronic disease that affects 415 million people worldwide. Despite treatment advances,diabetic eye disease remains a leading cause of vision loss worldwide. Diabetic macular edema (DME) is acommon cause of vision loss in diabetic patients. The pathophysiology is complex and involves multiplepathways that ultimately lead to central retinal thickening and, if untreated, visual loss. First-line treatment ofDME has evolved from focal/grid laser established by the Early Treatment of Diabetic Retinopathy Study(ETDRS) to intravitreous pharmacologic therapy. Landmark prospective clinical trials examining the effect ofintravitreous injections of vascular endothelial growth factor (VEGF) inhibitors in the treatment of DME havedemonstrated improved visual outcomes over focal grid laser. This course focuses on the scientific evidencetreatment of DME, disease pathophysiology, clinical course, current treatment standards, and emerging noveltherapeutic approaches.
| 1 | Newer concepts in understanding the Pathophysiology of DME | Dr. Swapnesh D Sawant |
| 2 | Newer diagnostic investigations in the management of DME | Dr. Nivean M |
| 3 | First line therapy in the management of DME | Dr . Mahesh Shanmugam P |
| 4 | Combination therapy in the management of DME | Dr. Manoj Khatri |
| 5 | Cataract surgery along with the management of DME | Dr. Mohan Rajan |
| 6 | Emerging trends in the management of DME | Dr. Viral Shah |
| 7 | Can Diabetic Retinopathy be reversed – Future directions!! | Dr. Rupesh Vijay Agrawal |
Leave a Comment